Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702691 | 0.90 | HTR6 (0.57) | HTR6MMP2MMP8MMP12MMP13 | |
| SCHEMBL5568656 | 0.86 | HTR6 (0.44) | HTR6MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL6669464 | 0.82 | ITGAV (0.48) | HTR6ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL6611408 | 0.82 | KMT2A (0.51) | HTR6MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL10727900 | 0.82 | HTR6 (0.56) | HTR6MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL5572760 | 0.79 | ALDH1A1 (0.48) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL697565 | 0.79 | ADRA1A (0.49) | RAB9AMMP12MMP1GAA | |
| SCHEMBL5286168 | 0.78 | HTR6 (0.55) | HTR6MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL30901411 | 0.77 | NPC1 (0.60) | HTR6MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL29210114 | 0.77 | NPC1 (0.60) | HTR6MEN1KMT2AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4169558-A | — | — | None | — | — | JP | disclosed |
| JP-61093145-A | — | — | None | — | — | JP | disclosed |
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-28 | — | — | US | disclosed |
| EP-3294704-B1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| US-20160332962-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-17 | — | — | US | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022782-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1118611-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0710652-B1 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| JP-H04169558-A | PRODUCTION OF OPTICALLY ACTIVE 1,2-PROPANEDIAMINE | TORAY IND INC | 1992-06-17 | — | — | JP | disclosed |
| JP-S6193145-A | METHOD OF SEPARATING AMINO ACID ENANTIOMER BY CHROMATOGRAPHY | FUNAKOSHI YAKUHIN KK | 1986-05-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | STS, SRR, SRM | HTR6 730/4885MEN1 4873/4885KMT2A 1434/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | HTR6 1766/4885MEN1 329/4885KMT2A 566/4885 |
| US-20160332962-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | STS, SRR, SRM | HTR6 730/4885MEN1 4873/4885KMT2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.